You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):ASC10-A對奧密克戎變異株、德爾塔變異株及早期病毒株都具有強效的細胞水平抗病毒活性
格隆匯 03-15 19:28

格隆匯3月15日丨歌禮制藥-B(01672.HK)發佈公吿,其抗新型冠狀病毒肺炎(COVID-19)口服雙前藥ASC10的業務進展如下:基於系列優化措施,ASC10的生產成本顯着下降,這對抗新冠藥物的可及性至關重要。

1.完成ASC10原料藥關鍵中間體的合成工藝優化。在保證質量的前提下,採用了生物酶催化綠色合成法,提升了關鍵中間體的合成收率,降低了有機溶劑的使用量,更利於環境保護。

2.完成ASC10關鍵生產設備利用率整體提升方案制定;完成連續化生產模式方案制定,旨在提升ASC10製劑的生產收率。

及3.已拓展ASC10原料藥中間體和其它物料供應商。最新實驗數據顯示ASC10-A對奧密克戎變異株(EC50=0.3μM)、德爾塔變異株(EC50=0.5μM)以及早期病毒株(EC50=0.7μM)都具有強效的細胞水平抗病毒活性。此外,最新實驗數據提示ASC10不會與其它常用藥物發生藥物-藥物相互作用。

ASC10是抗病毒核苷類似物ASC10-A的口服雙前藥,ASC10-A對新型冠狀病毒聚合酶(RdRp)有強效抑制作用。ASC10口服片劑是歌禮專有技術開發的產品。至今,歌禮已在全球範圍內提交了多項ASC10及其用途的專利申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account